Search This Blog

Monday, October 6, 2025

'Looking for leniency on your assassination charge? Just say you’re trans and watch the judge fawn'

 On Friday, we all learned a valuable lesson: if you’re a criminal looking for leniency in America, just claim you’re transgender.

The judge will even recognize your gender journey in the sentencing — like they’re giving out a “Most Improved” award at the end of soccer season. And much of the media will seamlessly move from “he” to “she,” as soon as said criminal gives them the thumbs up.

How are we still doing this in 2025?

California native Nicholas Roske crossed the country intending to murder Justice Brett Kavanaugh following the leak of the Supreme Court’s draft decision in the “Dobbs v. Jackson Women’s Health” case that overturned Roe v. Wade. He was sentenced on Friday to a mere eight years.

Nicholas Roske, attempted assassin of Supreme Court Justice Brett Kavanaugh, standing in a gun shop with two shotguns on the counter.Department of Justice

Remember Roske was busted outside of Kavanaugh’s Maryland home back in June 2022 toting a Glock pistol, ammunition, a tactical light, zip ties, pepper spray and burglary tools.

Though he didn’t follow through with the assassination and called 911 on himself, it was an eerie harbinger of leftist political violence to come.

The government recommended 30 years in prison, because traveling across the country to murder a Supreme Court Justice isn’t some casual brush with the law.

Nicholas Roske, who now identifies as a woman named Sophie, poses with his parents.

In this charged climate, it’s important to send a firm message to other nefarious actors motivated to harm or kill public officials. This should be a bipartisan sentiment.

Last month, Roske’s defense team conveniently revealed that he was trans and would like to be called Sophie — and exposed that our institutions are still slavishly devoted to the transgender ideology.

Judge Deborah Boardman considered Roske’s new identity while dishing out his light punishment.

“I am heartened that this terrible infraction has helped the Roske family… accept their daughter for who she is,” said Judge Boardman, according to the Daily Wire.

Hey, it was never about a man trying to murder a Supreme Court Justice and his family, it was about the would-be killer’s familial healing. And his gender identity being validated by his loved ones.

California native and would be Justice Kavanaugh assassin, Nicholas Roske now identifies as a woman and was given a mere eight years in prison.

It was, what ABC’s Matt Gutman might call, “very touching.”

Where’s Judge Judy when you need her?

After Judge Boardman’s ruling, the media fell in line recognizing Roske’s gender makeover without an ounce of skepticism.

NBC News served up an Orwellian headline that read, “Woman sentenced to 8 years in prison for attempting to assassinate Brett Kavanaugh.”

Various other outlets including CBS, ABC and the NYTimes referred to Roske, as “she” while The Guardian also called him a “woman” in their headline.

To quote the husband describing Jake from State Farm in the insurance giant’s old commercial, “well, she’s a guy…”

We know Roske isn’t a woman, they know he’s not a woman. And their behavior is cowardly.

NBC News, along with The Guardian referred to Roske as a “woman.”NBC News

It’s not 2021, when media outlets were coerced into respecting pronouns and a plethora of gender identities and Twitter suspended accounts for “misgendering” people. Those who refused to comply with the pronoun delusion, were canceled, deplatformed and branded transphobes.

News outlets need to decide if they are serving their readers and delivering facts or catering to a handful of militant activists who insist that men can become women simply because they declare it so.

Even on Fox News Sunday, the entire panel tripped over themselves to avoid a pronoun boobytrap. They all clumsily referred to the biological male in variations of gender neutral, “that person.”

Roske’s biological sex isn’t some fact that’s up for interpretation. It’s as objective as his hometown or age. He is, indeed, a man.

Then again, it’s the same media that genuflected before the pronouns of a deranged man who shot up a Minnesota Catholic grammar school, killing two children and leaving others with life threatening injuries.

Judge Deborah Boardman gave Brett Kavanaugh’s would be assassin, Nicholas Roske, a slap on the wrist, while respecting his pronouns.Shutterstock

For example, NBC News tweeted, “Police visited the Minneapolis shooting suspect’s home at least twice when she was a teen. But she had no criminal record, and all weapons were lawfully purchased.”

By participating in such charades, these media outlets have successfully done the bidding of the evil patriarchy, managing to blame criminal behavior of white men on women.

It’s a neat trick.

But why is gender dysphoria now a special consideration when it comes to our justice system?

And hey, what could go wrong after Judge Boardman exploited the idea of empathy, giving a slap on the wrist to someone who could have ignited an even more painful period in our nation’s history. She did so partially because his maniacal act was done while he was experiencing gender distress, and he’ll have to be in a men’s prison thanks to an executive order from President Trump.

Robin Westman, who identified as a woman, killed two children at a Minnesota catholic school before killing himself and media outlets still called the biological man, “she.”via REUTERS

This will be a green light for more bad people with bad intentions to take advantage of the good lefties who turn to mush at idea of a man finding his inner woman while committing violent acts.

And much of the media will be the useful idiots there to rubber stamp such dangerous decisions.

https://nypost.com/2025/10/06/opinion/looking-for-leniency-on-your-assassination-charge-just-say-youre-trans-and-watch-the-judge-fawn/

Health Care Down as Pfizer Compromise Optimism Fades

 Health-care companies fell, giving back some recent gains related to a compromise between the U.S. and one major drug maker.

Shares of Pfizer, which has agreed to sell Americans pharmaceuticals at a discount through a proposed TrumpRx website, fell by more than 3%.

Shares of health insurer Humana added to their recent gains.

Biotech firm Amgen slashed the price of its cholesterol medication by more than half for U.S. patients through a new medication-access program amid the Trump administration's call to lower drug prices.

https://www.morningstar.com/news/dow-jones/202510068224/health-care-down-as-pfizer-compromise-optimism-fades-health-care-roundup

US Department of War to invest $35.6 million in Trilogy Metals

 The U.S. Department of War (DOW) has agreed to invest approximately $35.6 million to advance exploration and development of critical mineral resources at Trilogy Metals Inc.’s (NYSE American:TMQ) (TSX:TMQ) Upper Kobuk Mineral Projects in Alaska, according to a press release statement issued Monday.

Under the binding letter of intent, the DOW will acquire approximately 10% ownership in Trilogy Metals through two parallel transactions. The department will invest $17.8 million directly in Trilogy in exchange for 8,215,570 units, each comprising one common share and three-quarters of a 10-year warrant. Additionally, the DOW will pay South32 Limited (ASX, LSE, JSE:S32) $17.8 million to purchase 8,215,570 existing Trilogy shares and secure options for additional shares. South32 has a market capitalization of $8.3 billion

The agreement stipulates that both Trilogy Metals and South32 will use the funds to advance the Upper Kobuk Mineral Projects, which are held by Ambler Metals LLC, a 50/50 joint venture between the two companies. South32 brings strong financial health to the partnership.

The transaction also includes provisions for discussions regarding the Ambler Access Project, a proposed 211-mile industrial-use road that would connect the Ambler Mining District to Alaska’s highway system. The DOW has committed to help facilitate financing for the road’s construction in coordination with the State of Alaska.

"This proposed partnership with the U.S. Government represents a significant milestone for Trilogy Metals and for the development of a secure, domestic supply of critical minerals for America in Alaska," said Tony Giardini, President and CEO of Trilogy Metals.

The transaction remains subject to regulatory and stock exchange approvals. Closing is expected following the reauthorization of the Defense Production Act by Congress and completion of a Foreign Ownership, Control, or Influence review by the U.S. Government. If these conditions are not met by March 31, 2026, the letter of intent will terminate.

The Upper Kobuk Mineral Projects are located in the Ambler Mining District of northwestern Alaska, which contains copper, zinc, lead, gold, silver, and cobalt deposits. 

https://www.investing.com/news/company-news/us-department-of-war-to-invest-356-million-in-trilogy-metals-93CH-4273871

The Progressive Flight From Reality

 by J. Peder Zane via RealClearPolitics,

Progressivism isn’t just an ideology; it’s also becoming a mental health condition.

Spiraling past the tendentious spin and lies that have long shaped American discourse on both sides of the aisle, the loudest voices on the left are losing the capacity to grasp reality. As a character in a recent Wall Street Journal cartoon put it: “You’ve got it all wrong. What I’m saying isn’t misinformation. It’s denial.

Take Illinois Governor JB Pritzker’s recent denunciation of “White House senior aides” for “sowing fear, intimidation and division” by, among other things, calling Democrats “fascists.” Given not just his party’s but his own frequent use of such rhetoric – comparing ICE agents to Nazis who disappear immigrants and vowing that Republicans “cannot know a moment of peace” – the jaw-dropping irony of his complaint was lost on no one, except, apparently, Pritzker and his allies. It raises the question: How did he think he could get away with this?

He is not alone. In recent weeks, progressives have been assailing President Trump’s very real attacks on free speech, without wrestling with the fact that they have long been the driving force behind cancel culture, hate speech codes, and broad-based censorship efforts.

They have been attacking Trump for weaponizing the justice system against his political enemies without coming to grips with the fact that they did exactly that during the Biden administration.

These efforts seem darker and more disturbed than the old political tactic of telling small lies to achieve larger truths. More than simply Trump Derangement Syndrome on steroids, they reflect the progressives’ flight from reality, into a world of their own making, a belief that the visions inside their heads are truer than what the rest of us can plainly see. Where sane people try to work through the ineluctable contradictions of their own thoughts – which many of the right are struggling to do in response to Trump’s overreach – progressives have abandoned this mental effort.

Poisoned by leftist arguments that there is no truth, only power, they believe they can make things so simply by saying them – which is crazy. How else to explain:

  • An August article in the New Yorker that stated: “Liberals used to be the counterculture; today, they’re the defenders of traditional norms and institutions.” That, of course, might come as news to those who disagree with the liberal view that sex is assigned at birth and who always thought equality, not equity, was the foundation of American liberty.
  • September column in the New York Times that quoted a University of Pennsylvania historian who claimed that Obama and Biden “didn’t think they had the power to disregard statutes passed by Congress and the text of the Constitution. They didn’t think they had the power to do things like treat the presidency as an office that permits its occupant to use the power of the state to reward friends and punish enemies and engage in self-dealing and enrichment.” Evidently, Professor Kate Shaw is unaware of the multiple cases brought against Donald Trump and his allies, the business dealings of Hunter Biden, or the first son’s pardon.

Consider Jimmy Kimmel’s infamous claim that Charlie Kirk’s left-wing assassin was actually MAGA. Given the mountains of evidence to the contrary, including the killer’s own words, it boggles the mind that anyone would come to this conclusion, much less say it in front of millions of people. But the talk show host was, in fact, articulating an unmoored view embraced by many voices respected on the left. Kimmel wasn’t simply trying to spin the news to help his side, he was repeating a story that makes sense if you have convinced yourself that only right-wing people engage in political gun violence and that your side is inviolately virtuous.

Unfortunately, this phenomenon gets even more troubling. As fears of political violence have intensified since Kirk’s murder, the New York Times has posted several pieces assassinating his character. One of its star content creators, Ezra Klein, for example, provided little pushback on a recent podcast as the racialist writer Ta-Nehisi Coates repeatedly labeled Kirk a “hatemonger.” The newspaper also published a long essay by Nikole Hannah-Jones, who led the paper’s controversial 1619 Project which tried to put slavery at the center of American history, which repeatedly called Kirk a bigot.

Her only evidence to support this inflammatory portrayal is one 168-word paragraph in a 2,568-word piece that cherry-picked, out-of-context snippets – he said ‘there’s a war on white people in this country’ he referred to a transgender athlete as an ‘abomination’ – to cast Kirk’s opposition to the woke agenda, gender affirming care and his concerns about black crime and Islam as “unabashed bigotry.”

To assess the quality of evidence, note that she repeats the long-debunked claims that Trump “called the white supremacists who rallied in Charlottesville, Va., ‘very fine people.’ ” To demonstrate that her views have wide currency, she writes that “Last year, The Washington Examiner, a conservative news outlet, published a column calling the organization Kirk co-founded, Turning Point USA, ‘one of the most destructive forces in Republican politics.’” What she ignored was that the author of that piece, Ben Rothove, published a short piece in the New York Times 16 days before her essay was published that declared, “I was wrong about Charlie Kirk.”

Hannah-Jones is, of course, entitled to her views – but not her own facts. It is telling that she and her editors thought it was appropriate to print a piece that made no effort to contextualize Kirk’s statements, or to try to understand why so many people in the world admired him. Their goal, instead, was to demonize an adversary by assertion. This is our truth. Perhaps more disturbing are two quotes in the piece that suggest Kirk’s murder was acceptable. “I cannot have empathy for him losing his life when he put mine at risk,” one black educator told Hannah-Jones.

“I firmly believe that no one should be killed for their beliefs, no matter how harmful those beliefs might be,” another person told her. “But we are watching our rights being stripped away. 

Such views, of course, resonate with those of thousands of others who celebrated Kirk’s murder; just as many progressives have cheered Luigi Mangione’s cold-blooded murder of UnitedHealthCare CEO Brian Thompson last December.

I hesitate to say that the Times was sanctioning Kirk’s assassination. But it is clear that progressives are proceeding down a dangerous path where facts, truths, and human decency are being overwhelmed by their dark desires.

https://www.zerohedge.com/political/progressive-flight-reality

Biomea Fusion reports 52-week results from Phase II diabetes trial

 Biomea Fusion, Inc. (NASDAQ:BMEA), currently trading at $2.67 after seeing its shares fall nearly 80% over the past year, reported new 52-week results Monday from its Phase II COVALENT-111 clinical trial evaluating icovamenib in adults with type 2 diabetes.

The COVALENT-111 trial is a double-blind, randomized, placebo-controlled study involving adults diagnosed with type 2 diabetes within the last seven years. Eligible participants had HbA1c levels between 7.0% and 10.5% and a body mass index between 25 and 40 kg/m². All participants had inadequate glycemic control despite lifestyle management and up to three antidiabetic medications. With a market capitalization of approximately $159 million, Biomea Fusion’s development programs are supported by a strong balance sheet, with InvestingPro analysis showing the company holds more cash than debt and maintains a healthy current ratio of 3.68.

The study assessed three dosing regimens of icovamenib: 100mg once daily for 8 weeks (Arm A), 100mg once daily for 12 weeks (Arm B), and 100mg once daily for 8 weeks followed by 100mg twice daily for 4 weeks (Arm C). A total of 267 patients received at least one dose and were included in the modified intent-to-treat population. Due to an interim clinical hold by the U.S. Food and Drug Administration, the topline efficacy analysis focused on 163 patients who completed at least 80% of their planned dosing.

The 52-week analysis primarily evaluated patients in Arms B and C who received 12 weeks of treatment (n=10) and were classified as having severe insulin-deficient diabetes. In this group, icovamenib achieved a mean reduction in HbA1c of 1.2% (p=0.01) sustained through Week 52. The greatest reduction was observed in Arm B (n=6), with a mean HbA1c decrease of 1.5% (p=0.01). In a subgroup of patients on GLP-1-based therapy who had not reached glycemic targets at study entry (n=11), icovamenib led to a 1.3% HbA1c reduction (p=0.05) sustained through Week 52.

The company reported that icovamenib maintained a favorable safety profile throughout the observation period, with no treatment-related serious adverse events or discontinuations due to adverse events.

Biomea Fusion stated that ongoing and upcoming studies include a food effect study (COVALENT-121) expected to complete by December 2025, and two Phase II trials (COVALENT-211 and COVALENT-212) planned to begin in the fourth quarter of 2025. 

https://www.investing.com/news/sec-filings/biomea-fusion-reports-52week-results-from-phase-ii-diabetes-trial-93CH-4273690